Clinical Trial Update: Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating fidaxomicin vs placebo for prevention of CDAD in adults undergoing hematopoietic stem cell transplantation; completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridium Difficile-associated Diarrhea

Drugs mentioned

• Fidaxomicin (fidaxomicin)

Snippet

Sponsor: Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Clostridium Difficile-Associated Diarrhea (CDAD) | Phase 3 | Status: COMPLETED | Results posted: 2016-04-12